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iMpRoveR: the integral Membrane 
protein Stability Selector
Steven p. D. Harborne1,2,6*, Jannik Strauss1,6, Jessica C. Boakes1,6, Danielle L. Wright1, 
James G. Henderson1, Jacques Boivineau3, Veli‑Pekka Jaakola4 & Adrian Goldman1,5*
Identifying stabilising variants of membrane protein targets is often required for structure 
determination. Our new computational pipeline, the Integral Membrane Protein Stability Selector 
(IMPROvER) provides a rational approach to variant selection by employing three independent 
approaches: deep-sequence, model-based and data-driven. In silico tests using known stability 
data, and in vitro tests using three membrane protein targets with 7, 11 and 16 transmembrane 
helices provided measures of success. In vitro, individual approaches alone all identified stabilising 
variants at a rate better than expected by random selection. Low numbers of overlapping predictions 
between approaches meant a greater success rate was achieved (fourfold better than random) 
when approaches were combined and selections restricted to the highest ranked sites. The mix of 
information IMPROvER uses can be extracted for any helical membrane protein. We have developed 
the first general‑purpose tool for selecting stabilising variants of α‑helical membrane proteins, 
increasing efficiency and reducing workload. IMPROvER can be accessed at http://impro ver.ddns.net/
IMPRO vER/.
Membrane proteins are key drug targets, but rational approaches to drug design against them have largely been 
hampered by a lack of high-resolution structures. Bottlenecks in solving membrane protein structures occur at 
every step, often because membrane proteins are unstable, especially in  detergent1. The well-established scanning-
mutagenesis approach has been highly successful at identifying stabilising variants. This brute-force trial-and-
error  method2 has led to improved expression, purification and ‘crystallisability’ of numerous membrane protein 
targets, often from the G-protein coupled receptor (GPCR) family (such as the β1-adrenoceptor2, 3, adenosine 
A2A
4 receptor and neurotensin  receptor5). Two-thirds of all GPCR structures solved to date have had at least 
one stabilising amino acid change introduced. However, these scanning approaches are expensive and labour-
intensive, which is a bottleneck for  industry6 and intractable for most academic laboratories.
Our solution was to create a computational tool that combines a number of bioinformatics techniques and 
prior data from membrane protein stabilisation studies to rank the likelihood of amino acid changes produc-
ing stabilising effects. Variants could then be prioritised based on rank. We anticipated that stabilising variants 
could be found with fewer experiments, increased speed and decreased cost and effort. Our new tool, the Integral 
Membrane Protein Stability Selector (IMPROvER), is a software package that takes sequence level information 
as input and produces a list of top-ranked stabilising variants (Fig. 1). It can also generate primer sequences 
required to make the variants by site-directed-mutagenesis. The methods used for selecting variants are based 
on the following three approaches: (1) deep-sequence analysis, (2) model-based analyses and (3) a data-driven 
analysis. Furthermore, we can use prior information about specific residues known to have a critical function in 
protein activity (or any other reason), and exclude these from selection (Fig. 1).
Results
Construction of IMPROvER modules. In the deep-sequence module of IMPROvER, highly redun-
dant multiple sequence alignments ( > 8, 000 sequences) were assembled to assess natural variation in protein 
sequence.  Covariance7 between residues and natural frequency of residues at a position were used to iden-
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tify potentially beneficial  substitutions8. In this module, we used the EVcoupling and EVmutation open-source 
 software7, 8.
In the model-based module, multiple input models were subjected to in silico saturation mutagenesis. A  G 
of unfolding was rapidly calculated for each  variant9. Sites with in silico improved thermostability in multiple 
models were ranked highest to help decrease bias from poorly modelled sites. In our tests, models were generated 
with comparative homology modelling where templates with correct fold were known (such as the GPCR test 
sets)10. Models for targets with unknown fold were generated using threading and ab-initio folding  strategies11.
In the data-driven module, data from three GPCR stabilisation campaigns were analysed for both stabilising 
and destabilising trends. The GPCR dataset comprised of stability measurements for the majority of amino acid 
positions in turkey β1 adrenergic  receptor12, human adenosine A2A  receptor13 and rat neurotensin receptor  15, 
when changed to alanine, or leucine if the residue at a position was natively alanine. Stability data for the A2A 
receptor were available for apo, agonist and antagonist bound states; for neurotensin receptor 1 for the agonist 
and apo states; and for β1 adrenergic receptor in the apo state only. On a position-by-position basis, both positive 
and negative effects on stability in GPCR stability datasets were correlated with bioinformatic information such 
as amino acid type, conservation, predicted topological position, predicted disordered region, predicted lipid-
contact and predicted helix–helix contact scores. The bioinformatics information was calculated using several 
open-source packages including the PSIPRED  suite14.
Whilst analysing the GPCR dataset, we observed that positions with amino acid conservation in the range of 
50–60% were most associated with increased stability, while positions with amino acid conservation in the range 
of 80–90% were most associated with decreases in stability (Fig. S1; Table S1). This observation makes sense: 
highly conserved residues are less tolerant to substitution as they are in critical locations for fold or function so 
residue substitutions will tend to be detrimental. Conversely, poorly conserved sites tolerate substitution. Thus, 
substitutions at moderately conserved residues have a higher likelihood of increasing stability.
In our analysis, we also found that substitution of residues G, T, A, Q, E and H were most associated with 
increases in stability (in descending order), and substitution of residues I, Y, W, D, C and V, were most associated 
with decreases in stability (in descending order) (Fig. S1). Similarly, when considering the topological location of 
residues, changes in transmembrane helices (TMH) most often stabilised, while changes in cytosolic helices most 
often destabilised. For the scoring method in this module, we found that amino acid identity, topological posi-
tion and disorder prediction were the best predictors of effect on stability compared to amino acid conservation, 
which was a poorer indicator of stabilising effect (Fig. 2A). However, testing against the GPCR dataset showed 
that known stabilising hits were highly ranked when all the scoring methods apart from disorder prediction were 
Figure 1.  Graphical schematic for steps in the IMPROvER pipeline. Scheme of variant selection using 
IMPROvER, highlighting the three main modules: deep-sequence (blue), model-based (green) and data-driven 
(red). Once positions have been selected, they are compared against a list of residues to be excluded (e.g. those 
known to be critical to function from the literature).
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combined (Fig. 2A). Therefore, this scoring method was the one used by the data-driven module for selecting 
variations to make.
Testing IMPROvER against the GPCR dataset. The GPCR dataset also allowed us to evaluate the suc-
cess of IMPROvER modules for correctly ranking stabilising and destabilising changes. For all methods, there 
was no strong correlation between stabilising rank (position after sorting by score) and the absolute thermo-
stabilisation in the GPCR dataset. Instead, we considered the number of confirmed stabilising changes that 
were grouped at the top of ranked lists produced by each selection method (Fig. 2B). The data-driven approach 
Figure 2.  Performance of IMPROvER for predicting stability. (A) Cumulative scatter plot and radar plot to 
highlight the effect of different weightings of bioinformatic information in scoring methods to successfully 
group stabilising hits in the top 5, 10 or 25% of ranked lists (orange, cyan or purple in radar plot, respectively). 
Methods successful at selecting stabilising residues have lines above random (black) in scatter plot or points 
further outwards than random (i) in radar plot. Scoring methods tested: i. random, ii. combined score (for 
amino acid, topology, conservation, predicted helix–helix contact and predicted lipid contact) iii. amino acid 
score (AA), iv. topology score (Top), v. conservation score (Cons), vi. disorder score (Disso), vii. predicted 
lipid contact score (Lip) and viii. predicted helix contact score (HH). (B) GPCR stabilising hit data versus rank 
(position in list after sorting by score) from the three different IMPROvER modules: deep-sequence (blue), 
model-based using either homology model or crystal structure (light and dark green, respectively) and data-
driven (red). Data are displayed with the Y-axis as a cumulative percent of stabilisers found (left) or true positive 
prediction rate (right). Data shown for random selection were the result of 10 random samplings of the dataset 
with the mean displayed (standard error is also indicated as grey shading).
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appears to be the most successful, grouping approximately 40% (Fig. 2B) of the known stabilisers (Fig. 2B) in the 
first quartile. This observation is expected as the scoring method was derived from this set: we also tested the 
modules on naive datasets (see below).
The model-based method also grouped approximately 40% of known stabilisers in the first quartile, using 
crystal structures as input models (Fig. 2B). This result is also expected, as IMPROvER is intended as a tool that 
precedes crystal structure solution, and the quality of the model would be very high for homology models of 
known GPCR structures. We therefore prepared models from templates with 10–30% sequence identity with 
the targets in the GPCR dataset. Using these models, this approach performed well for the top 5–10% of ranked 
sites, but not well in the top quartile (Fig. 2B).
Sites in the first quartile selected by the deep-sequence approach were not better than expected from random 
selections (equal with the black line in Fig. 2B). However, only predictions of changes to alanine (or leucine if 
already alanine) were considered, as this matched the input GPCR dataset. The deep-sequence approach selects 
the best residue for each site from all 20 amino acids, not just alanine. Therefore, this approach may perform 
better given the freedom to select the best amino acid for each site. This hypothesis was explored when in vitro 
targets were tested (below). The model data suggest that individually each method will identify 25–40% of the 
stabilising variants for a new protein target if the first quartile of ranked residues is used. As stabilised proteins 
typically have less than ten point mutations in total, we were reasonably confident that our approach would allow 
us to identify a sufficient number of stabilising variants to stabilise membrane proteins of unknown structure.
Stabilising variants of ClPPase selected with IMPROvER. Our first in vitro test protein was a mem-
brane-bound pyrophosphatase from Clostridium leptum (ClPPase) that was difficult to crystallise without fur-
ther stabilisation. Scores given by IMPROvER were used to rank sites in the protein, with variants in the top 
15% selected for stability testing (Table S2). 127 residues were specifically eliminated from testing as they were 
known to be critical in the mechanism of membrane-bound pyrophosphatases (Table S3)15–26, thus excluding 22 
high-ranking variants (Fig. 3A). The sites selected by the different approaches were mostly non-overlapping. In 
17 cases, sites were highly ranked by two different approaches, although the amino acid substitution was usually 
different (Fig. 3B). For the majority of overlapping cases, we selected the variant with the highest IMPROvER 
score and excluded the others, even if the amino acid change was different. 45 mutations were successfully intro-
duced into the ClPPase gene by site-directed mutagenesis, providing a random sampling of half the sites ranked 
in the top 15% by IMPROvER: 15 from deep-sequencing, 15 from model-based and 15 from data-driven modules.
Expression of the variants in yeast, membrane isolation and solubilisation in dodecyl maltoside (DDM) 
allowed us to assay the thermostability of these variants in crude extracts using green fluorescent protein (GFP) 
fluorescence. Stability testing was based on heating the sample to a defined temperature, removing heat-pre-
cipitated protein by centrifugation and assessing remaining protein in solution by in-gel fluorescence. Using a 
ten-temperature melting analysis based on this method, the apparent melting temperature ( Tm ) determined for 
ClPPase was 49.3± 0.9 ◦ C (Fig. 3D and Fig. S2). To facilitate rapid testing of variants, they were subjected to a 
challenge at a single temperature and the remaining GFP-signal compared to that of wild-type (Fig. S2). 14 of 
45 variants were identified as potentially stabilising. This selection was based on variants retaining over 55% of 
the wild-type GFP-signal, a cut-off determined by calculating the 95% confidence interval of all measurements 
in the dataset (Fig. 3C and Fig. S3).
To confirm initial hits as stabilising and gain an understanding of how successful the single-temperature assay 
was for identifying hits, we determined the Tm for 21 of our variants using ten-temperature melting analyses 
(Table 1; Fig. 3D and Fig. S4). These 21 comprised 14 identified as stabilisers, 2 destabilisers and 5 neutral from 
the single-temperature assays. Only variants increasing the Tm by ≥1.3 ◦ C (average SEM of Tm ) compared to 
wild-type were considered stabilising in the ten-temperature assay. With data from the ten-temperature assay 
factored in, the overall success rate for selecting stabilising variants of ClPPase was 27%, which corresponds to 
12 stabilising variants found. In contrast, we only found 2 destabilising variants (4% rate).
Variant G130A had the biggest increase in Tm of 13.0 ± 1.4 ◦ C, followed by F20Y and G130S with increases 
of 9.1 ± 1.5 ◦ C and 8.1 ◦ C, respectively (Table 1; Fig. 3D,E and Fig. S4). The false-positive and false-negative 
rates of the single-temperature assay were both 15% (Fig. S3). The different approaches were similarly powerful 
at ranking variants with success rates of 20%, 33% and 27%, for deep-sequence, model-based and data-driven, 
respectively (Fig. 3C and Fig. S3). These success rates are 3–4 times greater than expected by random selection 
(7.6% in GPCRs) and similar to the in silico testing of the GPCR dataset (Fig. 2B). Furthermore, all top stabilising 
hits retained or improved upon wild-type PPi hydrolysis activity (Fig. 3E and Fig. S3C).
Understanding why certain amino acid substitutions stabilise ClPPase is difficult without an experimental 
three-dimensional structure. However, if the positions of the variants are mapped to our best comparative homol-
ogy model, all stabilising variants cluster on the opposite side of the protein from the dimer interface, close to 
regions that interact with lipid (Fig. 3F,G). Furthermore, 6 of the 12 stabilising variants (G130A, G130S, R290F, 
F20Y, S113A and R109W) cluster at the interface between helices 1, 3, 4 and 7 (Fig. S5). This region includes the 
variants that stabilise ClPPase the most. We have previously shown that this part of the protein is particularly 
mobile in molecular dynamics simulations using the Thermotoga maritima  homologue27.
It is possible that these six variants act to stabilise helix–helix interaction, particularly around TMH1. G130 
(15% conserved) stabilises ClPPase when substituted to serine or alanine, possibly constraining movement of 
TMH4 relative to TMH1, by replacing the helix-breaking glycine residue (Fig. S5A,B). F20 (10% conserved) on 
TMH1 stabilised when substituted to tyrosine, possibly by providing hydrogen bonding to TMH7 R290 (34% 
conserved), increasing the rigidity of this region (Fig. S5C). Interestingly, the R290F substitution also increases 
stability, possibly due to energy reduction on removing repulsion between R290 and R24, by increasing hydro-
phobic packing between TMH4 and TMH7, or both (Fig. S5D). Both S113 (2% conserved) and R109 (96% 
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Figure 3.  Using IMPROvER to identify stabilising variants of ClPPase. (A) Comparison of residues selected 
by IMPROvER modules but excluded due to prior known critical role. (B) Comparison of residues selected by 
IMPROvER that are overlapping between the different modules. (C) Statistical analysis of all data collected for 
ClPPase variant in-gel GFP-based stability assay, or grouped by prediction module. Each data point represents a 
biological repeat of the single-temperature stability analysis (single-temperature challenge at 50 ◦ C normalised 
to intensity of sample incubated on ice). In each case the median of all points is displayed with 95% confidence 
intervals represented as whiskers. (D) wild-type (WT) ClPPase, and representative variant curves of three 
stabilisers and one destabiliser, assayed by ten-temperature stability analysis (panel insert and Fig. S4) after 
temperature challenge at 20, 30, 40, 45, 50, 55, 60, 70, 80, and 90 ◦ C. Data in each curve are normalised to 
the intensity of sample incubated on ice. The wild-type curve was collected as an average of eight biological 
repeats and variants were three biological repeats. Please see Fig. S2A for an uncropped gel image. (E) Tm of 
top stabilising variants (and the destabilising variant L142P) versus their specific PPi hydrolysis activity. Error 
bars in all panels D and E are representative of SEM. Stabilising variants that retain or improve on wild-type 
activity cluster in the top right quadrant. (F) View in the plane of the membrane and (G) perpendicular to the 
membrane at the most stabilising variant positions (coloured balls) mapped to the best comparative homology 
model of ClPPase.
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conserved) stabilise ClPPase when substituted with alanine or tryptophan, respectively, and are at the C-terminus 
of TMH3 in an interface between TMH3 and TMH1. It is likely they stabilise the interaction between these helices 
by improving the hydrophobic packing in this region (Fig. S5E,F). Therefore, it appears that all these substitutions 
act to stabilise through a similar mechanism: increasing rigidity in the helix–helix interfaces between TMHs 1, 
3, 4 and 7. This may explain why combining these variants together did not additively increase protein stability 
as seen in the G130A/F20Y combined variant (Fig. S3C).
Stabilising variants of hENT1 selected with IMPROvER. Our second in vitro test protein was the 
human equilibrative nucleoside transporter isoform 1 (hENT1). As with ClPPase, IMPROvER was used to rank 
variants for stability testing (Table S4). 36 positions were excluded based on the literature (Table S5)28–39, thus 
eliminating eight high-ranking variants (Fig. 4A). A larger number of 36 hENT1 residues were highly ranked 
by more than one approach compared to ClPPase, possibly because hENT1 is much shorter, and in total more 
residues were selected for study (Fig. 4B). Unlike for ClPPase, we excluded overlapping variants only if the amino 
acid substitution was the same (5 cases). 95 mutations were successfully introduced into the hENT1 gene by 
site-directed mutagenesis, providing a random sampling of half the sites ranked in the top 40% by IMPROvER. 
However, due to the extra technical requirements of Bacmid formation during expression in insect cells, only 
75 viruses were generated. Of these, 41 displayed GFP-fluorescence localised at the cell membrane (Fig. 4C and 
Fig. S6), bringing the tally down to a random sampling of a fifth of the sites ranked in the top 40%: 10 deep-
sequence, 7 model-based and 24 data-driven.
hENT1 variants were expressed in insect cells, solubilised in DDM and single-temperature stability assays 
carried out using the GFP-signal relative to that of the wild-type. 12 out of 41 variants tested were classified for 
further stability testing, an initial success rate of 29% (Figs. S7, S8A). This selection of stabilising hENT1 variants 
was based on retention of over 63% of the wild-type GFP-signal, a cut-off determined by calculating the 95% 
confidence interval of all measurements in the dataset (Fig. 4D).
The apparent Tm determined for wild-type hENT1 was 44.6 ± 0.6 ◦ C (Table 2; Fig. 4E and Fig. S9), using the 
ten-temperature stability assay. Using results from the single-temperature assay for classification, all apparent 
stabilising, several neutral and several destabilising variants were tested using the ten-temperature assay. Increases 
in hENT1 stability were modest compared to those observed for ClPPase, with the effects being 2.6 ± 1.3 ◦ C 
(K263A), 2.2 ± 0.7 ◦ C (N30F) and 1.2 ± 0.8 ◦ C (E247M) (Table 2; Fig. 4E, Figs. S8B, S9). Using a 0.9 ◦ C cut-off 
(average SEM Tm ), five hENT1 variants were considered to be stabilising (Table 2). With the relaxation of selec-
tion to the top 40% of sites and the sparsity of coverage, IMPROvER was less successful at predicting stabilisation 
Table 1.  Results from ten-temperature melting analysis of ClPPase variants. aAverage Tm was calculated 
from individual Tm estimated for each individual repeat by fitting with a four-parameter dose-response curve 
(variable slope) by non-linear least-squares fitting in the python package scipy.stats. bFor n > 1: standard error 
of the mean (SEM) shown. cFor n > 1: error calculated and propagated as detailed in “Methods and materials” 
section.
Module Variant Tm ( ◦C)a Tm error ( ±◦C)b Tm ( ◦C) Tm error ( ±◦C)c Repeats (n) Status
n/a Wild-type 49.3 0.9 0.0 1.2 8 n/a
Deep-sequence S113A 53.6 2.8 4.3 3.0 3 Stabilising
Deep-sequence S273V 48.8 – − 0.5 – 1 Neutral
Deep-sequence G130S 57.4 – 8.1 – 1 Stabilising
Deep-sequence S371K 50.6 – 1.3 – 1 Neutral
Deep-sequence F20Y 58.4 1.2 9.1 1.5 3 Stabilising
Model-based V81W 50.5 – 1.2 – 1 Stabilising
Model-based R463W 51.1 1.3 1.8 1.6 3 Neutral
Model-based L142P 44.0 0.5 − 5.3 1.0 3 Destabilising
Model-based L151I 49.7 1.2 0.4 1.5 2 Neutral
Model-based V693Y 51.4 – 2.1 – 1 Stabilising
Model-based R109W 52.7 1.7 3.4 1.9 3 Stabilising
Model-based R290F 50.5 – 1.2 – 3 Stabilising
Model-based D468F 52.0 0.6 2.7 1.1 1 Stabilising
Model-based I501L 50.6 – 1.3 – 1 Neutral
Model-based G179A 52.9 1.5 3.6 1.7 3 Stabilising
Data-driven A492L 47.7 – − 1.6 – 1 Destabilising
Data-driven A14L 48.4 – − 0.9 – 1 Neutral
Data-driven G31A 51.0 – 1.7 – 1 Stabilising
Data-driven A319L 51.5 – 2.2 – 1 Stabilising
Data-driven G130A 62.3 1.1 13.0 1.4 3 Stabilising
Data-driven A114L 50.2 – 0.9 – 1 Neutral
Combined G130A+F20Y 59.6 1.8 10.3 2.0 3 Stabilising
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Figure 4.  Using IMPROvER to identify stabilising variants of hENT1. (A) Assessment of residues selected as sites 
for variation by multiple modules in the IMPROvER pipeline. (B) Comparison of which residues were predicted 
by IMPROvER modules but excluded due to prior known critical role. (C) Representative example of the GFP-
fluorescence observed in Sf9 insect cells expressing GFP-tagged hENT1 variants (cells were expressing variant E264A). 
(D) Statistical analysis of data collected for hENT1 variant in-gel GFP-based stability assay together, wild-type alone 
or separated by the module that selected it. Each data point represents a biological repeat of the assessment of protein 
surviving after being challenged with a temperature of 50 ◦ C compared to 4 ◦ C sample. In each case the median of 
all points is displayed with 95% confidence intervals represented as whiskers. (E) Wild-type (WT) hENT1 stability 
assayed by in-gel GFP analysis (panel insert) after temperature challenges at 30, 45, 40, 45, 50, 55, 60, 65, 70, 75, 80 
and 85 ◦ C. Wild-type and curves were collected as an average of 12 repeats, whereas variant curves were collected 
as an average of 2–5 repeats. Double banding pattern on SDS-PAGE attributed to glycosylation of  N4828. The sum of 
intensities for both bands is used as a marker of stability. Data in each curve are normalised to the intensity of sample 
incubated on ice. Please see Fig. S7A for an uncropped gel image. (F) Scatter plot of hENT1 variant stability versus 
amount of radiolabelled specific inhibitor [3H]-NBMPR bound in the membrane relative to wild-type. Error bars in 
panels (E) and (F) are representative of SEM. (G) View in the plane of the membrane and H) perpendicular to the 
membrane at most stabilising variant hits mapped to the crystal structure of dilazep bound hENT1 (PDB: 6OB7)40. 
Residues E247 and K263 were absent from hENT1 crystal structures, and so the closest residue visible to the missing 
one has been used (residues 240 and 281, respectively).
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than for the ClPPase case (12%). However, if only the top 10% of ranked sites are considered that rate increases 
to 16%, over double that expected for random selections (7.6% in GPCRs). The model-based approach was most 
successful with a rate of 43%, followed by data-driven at 8% (Fig. 4E and Fig. S9). Of the variants suggested by 
the deep-sequence module, none we tested were stabilising. We found 15 destabilising hENT1 variants, more 
than ClPPase, but at a 36% rate, this was still lower than expected for random selections (48.5% in GPCRs).
As with ClPPase, we wanted to rationalise why the amino acid substitutions identified were able to stabilise 
hENT1. When we started this work, no crystal structure of hENT1 was available. Recently, the structure of 
hENT1 has been  solved40, which allows us to map the positions of successful stabilising variants to the structure 
(Fig. 4G,H). We observed a cluster of N30 (83% conserved) and L27 (56% conserved) on TMH1, which stabilised 
hENT1 when changed to phenylalanine or glutamate, respectively (Fig. S10A). These substitutions are likely to 
stabilise TMH1 by improving packing between it and adjacent helices. It should be noted that the L27E variant 
abolished NBMPR binding, whereas N30F did not (Fig. 4F and Fig. S8C). Although L27 is close to the NBMPR 
binding site, the side-chain is on the opposite side of the helix facing the protein-lipid interface, not into the 
binding site (Fig. S10A). The second cluster of sites included E247 (18% conserved) and K263 (2% conserved), 
which stabilised hENT1 when substituted to methionine or alanine, respectively. These sites are located in the 
intracellular domain between helices 6 and 7. This entire region (residue 243–274) was deleted from the crystal-
lographic  constructs40, and is likely to be unstructured. The E247M or K263A variants presumably stabilise the 
protein by reducing conformational flexibility in this region. Although we did not test it in the ten-temperature 
stability assay, it is notable that E265A that was indicated to be stabilising by the single-temperature assay is also 
part of this loop.
Stabilising variants of hPTH
1
R selected with IMPROvER. Our third in vitro test protein was the 
human parathyroid hormone receptor isoform 1 ( hPTH1R ) a family B GPCR. A hPTH1R construct in which 
the N-terminal extracellular domain had been replaced with a BRIL fusion was used for the introduction of 
stabilising variants. Only the top 10% of sites suggested by IMPROvER were considered for introduction into 
hPTH1R (Table S6). 32 positions were excluded based on the literature (Table S7)41–46, thus eliminating three out 
of the 30 highest-ranking variants (Fig. 5A). None of the remaining sites were overlapping predictions between 
different IMPROvER modules (Fig. 5B). However, unlike ClPPase and hENT1, different variations at the same 
site were allowed if highly ranked, which occurred in two cases (G188 and T427). 20 of the remaining variants 
were successfully introduced by site-directed mutagenesis, and showed clear GFP-fluorescence when expressed 
in Sf9 insect cells (Fig. 5C): 9 from deep-sequencing, 5 from model-based and 5 from data-driven modules.
The apparent Tm determined for wild-type BRIL-PTH1R solubilised in DDM was 38.7 ± 0.8 ◦ C (Fig. 5E and 
Fig. S11). Therefore, single-point stability assays were performed at 39 ◦ C for all variants, and GFP-signal relative 
to that of the wild-type analysed. 10 out of 20 variants were potentially stabilising as they retained over 63% of 
the wild-type GFP-signal, a cut-off determined by calculating the 95% confidence interval of all measurements in 
the dataset (Fig. 5D). These ten variants and two borderline cases were tested using the ten-temperature stability 
assay, confirming eight variants of PTH1R with an increase in Tm of > 1.1 ◦ C (average SEM of Tm ), an overall 
success rate of 40% (Table 3, Table S6; Fig. S11). The variant S198M had the biggest increase in stability with a 
Table 2.  Results from ten-temperature melting analysis of hENT1 variants. aAverage Tm was calculated 
from individual Tm estimated for each individual repeat by fitting with a four-parameter dose-response curve 
(variable slope) by non-linear least-squares fitting in the python package scipy.stats. b For n > 1: standard error 
of the mean (SEM) shown. c For n > 1: error calculated and propagated as detailed in “Methods and materials” 
section.
Module Variant Tm ( ◦C)a Tm error ( ±◦C)b Tm ( ◦C) Tm error ( ±◦C)c Repeats (n) Status
n/a Wild-type 44.6 0.7 0.0 0.9 12 n/a
Deep-sequence I380V 42.0 0.1 − 2.5 0.6 2 Destabilisng
Deep-sequence M306T 41.3 0.1 0.4 1.8 2 Neutral
Deep-sequence G225V 42.1 0.1 − 1.0 0.9 2 Destabilisng
Deep-sequence S321T 44.9 1.7 − 2.5 0.6 2 Destabilisng
Model-based R233L 37.1 1.6 − 3.8 0.6 2 Destabilisng
Model-based S152L 42.7 1.3 − 1.9 1.4 5 Destabilisng
Model-based E247M 45.8 0.6 1.2 0.8 4 Stabilising
Model-based N30F 46.8 0.4 2.2 0.8 5 Stabilising
Model-based L27E 45.5 0.7 0.9 0.9 5 Stabilising
Data-driven A401L 46.3 0.7 1.7 1.0 2 Stabilising
Data-driven T336A 43.9 0.7 − 0.7 0.9 5 Neutral
Data-driven Q246A 47.6 1.1 0.2 0.9 5 Neutral
Data-driven F153A 40.8 0.1 − 7.5 1.7 2 Destabilisng
Data-driven G207A 43.6 0.7 − 3.3 0.6 2 Destabilisng
Data-driven A88L 45.2 0.7 0.8 0.9 5 Neutral
Data-driven K263A 47.2 1.1 2.6 1.3 5 Stabilising
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3.4 ± 1.1 ◦ C increase in Tm , followed by F288A, G323A and G188Y (2.8 ± 0.7 ◦ C, 2.8 ± 0.6 ◦ C and 2.5 ± 0.7 ◦ C, 
respectively). These increases in stability are relatively modest in comparison to those observed for ClPPase, 
but similar to hENT1. The model-based and data-driven approaches performed best with success rates of 60% 
Figure 5.  Using IMPROvER to identify stabilising variants of hPTH1R . (A) Assessment of residues selected 
as sites for variation by multiple modules in the IMPROvER pipeline. (B) Comparison of which residues were 
predicted by IMPROvER modules but excluded due to prior known critical role. (C) Representative example of 
the GFP-fluorescence observed in Sf9 insect cells expressing GFP-tagged hPTH1R variants (cells were expressing 
variant Q401A). (D) Statistical analysis of data collected for hPTH1R variant in-gel GFP-based stability assay 
together, wild-type alone or separated by the module that selected it. Each data point represents a biological 
repeat of the assessment of protein surviving after being challenged with a temperature of 39 ◦ C compared to 
4 ◦ C sample. In each case the median of all points is displayed with 95% confidence intervals represented as 
whiskers. (E) Wild-type (WT) hPTH1R stability assayed by in-gel GFP analysis (panel insert) after temperature 
challenges at 4, 34, 36, 38, 40, 42, 45, 54, and 60 ◦ C. Wild-type and variant curves were collected as an average of 
three repeats. Data in each curve are normalised to the intensity of sample incubated on ice. Please see Fig. S11A 
for an uncropped gel image. (F) Barchart of hPTH1R variant Tm relative to wild-type. Error bars in panels 
(E) and (F) are representative of SEM. (G) View in the plane of the membrane and (H) perpendicular to the 
membrane at most stabilising variant hits mapped to the crystal structure of hPTH1R (PDB: 6FJ3)47.
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15165  | https://doi.org/10.1038/s41598-020-71744-x
www.nature.com/scientificreports/
and 50%, respectively. The deep-sequence approach was less successful for hPTH1R with a success rate of 22%. 
None of the PTH1R variants tested in ten-temperature stability assays were destabilising and only one variant 
had a significantly decreased survival in single-temperature assay, a very low rate of 5% destabilisers selected.
Rationalisation of the stabilising PTH1R variants was possible by mapping their positions to the recently 
solved PTH1R crystal structure (PDB: 6FJ3; Fig. 5G,H)47. As with ClPPase and hENT1, we observed clustering 
of certain stabilising variants. For example, F288 (35% conserved) and F291 (38% conserved) are one helix turn 
apart from one another on TMH3, and are involved in the helix–helix interaction between TMH2 and TMH3 
(Fig. S10B). Mutation to alanine or threonine, respectively, likely increases stability by improving the helix–helix 
packing interaction between TMH2 and TMH3. Furthermore, G188 (1% conserved) and S198 (89% conserved) 
are both on TMH1, with G188 facing into a void between TMH1 and TMH2 and S198 involved in the helix–helix 
interaction between TMH1 and TMH7 (Fig. S10C). Notably, the position G188 has previously been shown to 
assist PTH1R stability, and was mutated to alanine in the active state structure of PTH1R solved by cryo-EM48. 
Here, both G188Y and G188K variants were tested, both drastic changes that add bulky charged or hydrophilic 
groups, and both changes increased stability. It is likely that variation at G188 and S198 increases stability in 
PTH1R by increasing rigidity in TMH1 by improving helix–helix packing on either side.
Discussion
Numerous methods have been used to identify stabilising variants of membrane proteins, with scanning-
mutagenesis being arguably the most successful. Directed evolution by random mutagenesis has also shown 
some  success49, 50. These in vitro methods, although successful, are time and resource consuming, or suffer from 
biases that restrict the variations possible or the type of targets that can be worked  on51. Here, we describe a 
new computational tool called IMPROvER, the first general-purpose tool to rapidly select stabilising variants of 
multi-pass α-helical membrane proteins in silico for structural and biophysical characterisation.
Methodology, performance and use of the IMPROvER software. All three modules identified sta-
bilising variants better than random (Fig. 2B). Predictions from the different modules were mostly non-overlap-
ping, as they interrogated protein sequence space differently. Thus, the predictive power was additive, allowing a 
success rate of as much as fourfold above random for ClPPase and hPTH1R.
We specifically chose a broad range of top-ranked residues to calibrate the correlation between calculated 
rank position and stabilisation: for hENT1 in the top 40%, for ClPPase in the top 15% and hPTH1R the top 
10%. Overall, the IMPROvER rank scores do not correlate directly with the experimentally determined Tm 
(Tables S2 and S4) and thus do not provide exact predictions of stability. Rather, they guide a rational approach 
to selecting sites, and the sites found by IMPROvER and those used for  crystallography40 are correlated. For 
instance, both E247M and K263A are in the loop deleted in the hENT1 crystal structure, and N288K, ranked 
10th by IMPROvER, was used in the structure solution of hENT1. We nonetheless had much higher success rates 
for hPTH1R and ClPPase than hENT1, likely due to the more stringent selection criteria.
For researchers wishing to use IMPROvER on their membrane protein targets, we suggest equal selection of 
predictions from each of the IMPROvER modules. Furthermore, those selections should be in the top 5–10% of 
predicted sites. For example, the top ten ranked selections should be taken from each of the IMPROvER modules 
for a membrane protein of 300 amino acids to provide 30 sites total as we did for hPTH1R . We anticipate success 
rates of 25–40% in line with our test cases if this method is followed.
Table 3.  Results from ten-temperature melting analysis of hPTH1R variants. aAverage Tm was calculated 
from individual Tm estimated for each individual repeat by fitting with a four-parameter dose-response curve 
(variable slope) by non-linear least-squares fitting in the python package scipy.stats. bFor n > 1: standard error 
of the mean (SEM) shown. cFor n > 1: error calculated and propagated as detailed in “Methods and materials” 
section.
Module Variant Tm ( ◦C)a Tm error ( ±◦C)b Tm ( ◦C) Tm error ( ±◦C)c Repeats (n) Status
n/a Wild-type 38.7 0.8 0 1.1 3 n/a
Deep-sequence G188Y 41.2 0.7 2.5 0.7 3 Stabilising
Deep-sequence M189L 39.1 0.9 0.4 0.9 3 Neutral
Deep-sequence G188K 40.3 1.2 1.6 1.2 3 Stabilising
Deep-sequence A274D 39.1 0.1 0.4 0.1 3 Neutral
Model-based S198M 42.1 0.8 3.4 1.1 3 Stabilising
Model-based F291T 40.9 0.9 2.2 1.2 3 Stabilising
Model-based D251R 41.7 1.5 3.0 1.6 3 Stabilising
Model-based E260R 39.7 1.5 1.0 1.7 3 Neutral
Data-driven Q401A 40.7 0.2 2.0 0.2 3 Stabilising
Data-driven F288A 41.5 0.7 2.8 0.7 3 Stabilising
Data-driven E391A 39.4 0.2 0.7 0.2 3 Neutral
Data-driven G323A 41.5 0.6 2.8 0.6 2 Stabilising
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Identification and use of non‑additive effects. Stabilising variants clustered together in three-dimen-
sional space in protein structure in ClPPase, hENT1 and hPTH1R (Figs. 3F, 4G, 5G); certain parts of the pro-
teins, such as the 246–284 loop in hENT1, seem particularly unstable. Stabilising variations can have non-addi-
tive effects, such as two negative charges that interact, where changing one half may impart much or all of the 
effect of changing both. This has been observed in  GPCRs2, 6, and appears to be true when trying to combine 
the two most stabilising variants of ClPPase (F20Y and G130A). A rational approach to combining stabilising 
variants together is important, and we have previously implemented the powerful statistical method of fractional 
factorial analysis for such a combination of effects in membrane  proteins52. Our current version of IMPROvER 
is thus the first step in our pipeline for efficient protein stabilisation engineering.
In GPCRs, a number of ‘hot-spots’ are already known where specific variation often confers stability. Such 
data are not yet available for other membrane protein families but the data generated by using IMPROvER will 
begin to fill these gaps in our understanding. The TMH 1/3/4/7 interface in membrane-bound PPases, and the 
two clusters identified in nucleoside transporters, may be such ‘hot-spots’.
Comparison of IMPROvER to other computational methods. A number of the other in silico meth-
ods for selecting stabilising variants are also available. For example, the use of deep-sequence analysis combined 
with organism growth temperature to guide the introduction of thermophile specific amino acid adaptations 
into mesophilic homologues was successful for the stabilisation of tetracycline transporter (TetL) from Bacillus 
subtilis53. The major drawback of this approach is the requirement for thermophilic versions to exist in nature, 
which is not always true for higher eukaryotic targets.
There have also been a number of other in silico approaches, mainly focussing on selecting stabilising variants 
of GPCRs. For example, the use of molecular dynamics combined with statistical thermodynamics successfully 
predicted two highly stabilising variants of A2AR prior to experimental  confirmation54. This method took advan-
tage of existing crystal structures of A2AR to perform calculations, thus, would not be appropriate for novel tar-
gets. Similarly, methods based on ligand induced transmembrane conformational changes (LiTiCOn) in GPCRs 
were used to create conformational ensembles of models for a number of GPCRs. Those models were then used 
for in silico identification of stabilising variants that could be confirmed from prior experimental  information55.
More recently, machine-learning approaches have been applied, in which the existing GPCR dataset of sta-
bilising variants was used as the training set to successfully identify stabilising variants in naive  sequences56. 
One piece of software that has used this approach is the software CompoMug (Computational Predictions of 
Mutations in GPCRs)57, which showed a 25% success rate for the identification of stabilising 5-HT2C variants 
for crystallographic study. Furthermore, CompoMug also uses a combined approach similar to IMPROvER, 
with modules equivalent to the deep-sequence, model-based and data-driven IMPROvER modules used in 
 combination57. However, the underlying software used for calculations in each of these modules is not the same 
between CompoMug and IMPROvER. Importantly, we have validated that IMPROvER works across structur-
ally distinct α-helical membrane protein targets not just GPCRs, and our success rates are comparable or better 
than these other pieces of software.
Conclusions and future outlook. There will always be a need for the stabilisation of recalcitrant mem-
brane protein targets, like ClPPase, hENT1 and hPTH1R , and using a combination of tools is often necessary 
for success. These targets are important not only for high-resolution structure determination, but also other bio-
physical techniques, including but not limited to, surface plasmon resonance, isothermal titration calorimetry 
and microscale thermophoresis.
The dataset used for constructing the scoring matrix in the data-driven approach is currently limited as, 
although painstakingly collected, it was obtained from just three GPCRs. This precludes using a neural network 
approach, as it would likely be biased towards GPCR stability. Instead, we extracted a linear scoring matrix, 
allowing us to observe trends in membrane protein stability and to devise a computationally-efficient tool that 
helped us stabilise three membrane proteins with different folds and modes of action. To apply a neural network 
approach that would work broadly with membrane proteins as has been done for  GPCRs56–58 would require access 
to large systematic stabilisation datasets, with a record of both stabilising and destabilising variants of membrane 
proteins from diverse folds. We hope to increase the reporting, sharing and depositing of such data by releasing 
IMPROvER for use in the academic community http://impro ver.ddns.net/IMPRO vER/.
IMPROvER lowers the experimental burden associated with discovering stabilising variants of membrane 
proteins. Thus, the upper limit of target amino acid length is much greater than previously used in scanning 
approaches: for example ClPPase, which we have successfully stabilised here, is dimeric and 700 residues long, 
and there is no intrinsic reason that IMPROvER cannot be used on membrane protein complexes. Furthermore, 
both the deep-sequence and model-based approaches of IMPROvER are not just restricted to alanine substitu-
tions, broadening the scope of potential changes. Finally, we have shown that IMPROvER successfully stabilises 
helical multi-pass membrane proteins from diverse folds, because it uses bioinformatic information that can be 
extracted from any helical membrane protein. Thus, we have developed a general-purpose tool.
Methods and materials
Deep‑sequence approach. The deep-sequencing module of IMPROvER builds on the EVmutations 
 software8, a module of the larger EVcouplings package for evolutionary covariance  analysis7. In the package, 
the UniProt90 database is iteratively searched by  JackHMMER59, allowing the identification of distantly related 
sequences, an important aspect for making evolutionary comparisons. The EVcoupling module plmc is used to 
construct a matrix weighted scoring for each position: how alike each position in the query sequence is to the 
consensus. EVmutation is then used to make a prediction whether a position would be better if it were changed 
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to one of the other amino acids, calculated by comparing the current amino acid at a position to the amino acid 
consensus from alignment. In this analysis, infrequently used, potentially detrimental amino acid side-chains 
are selected for substitution to more frequently used ones. The program is essentially looking for ‘odd-ones-out’. 
The selections may improve protein stability or may be beneficial in other ways (assisting expression, improving 
activity or speeding-up folding). No prior structural information is required. IMPROvER is currently configured 
to only take variants predicted to be stabilising with a normalised score above 70%.
Model‑based approach. In this module, the software package FoldX was used for in silico mutagenesis 
and free-energy  calculations9. First, all input models were energy minimised by side-chain optimisation using 
the Repair module of FoldX. The models were then run through the AlaScan module of the FoldX, which esti-
mates the  G change (wild-type—variant) in unfolding energy for each position if it were changed to alanine. 
Positions were sorted based on the most negative average  G change, i.e. the highest average stabilising effect. 
Positions that had a normalised score above 70% were mutated to every other amino acid using the PositionScan 
module of FoldX. To make calculations less computationally expensive, PositionScan was only implemented on 
the single best model (the model with lowest free energy of unfolding after minimisation). All output models 
from PositionScan were then energy minimised by side-chain optimisation using the Repair module of FoldX 
once again, removing bad clashes introduced by in silico mutagenesis. The energy of unfolding for these models 
were then compared to energy of unfolding for wild-type to assess  G changes. Results for each position were 
sorted to select the best amino acid substitution for each of the selected sites.
Data‑driven approach. A GPCR dataset provided a single stability measurement for most of the positions 
in human adenosine A2A receptor ( A2AR ), rat neurotensin receptor 1 (NR1) and turkey β1 adrenergic receptor 
( β1AR ). Stability data for A2AR were available in the apo, agonist and antagonist bound states, for NR1 in the 
agonist and apo states and for β1AR only in the apo state. We considered each of these sets of data to be inde-
pendent as they are in different conformations, thus have differing tertiary structures. This provided just under 
2,000 mutation data points, capturing both stabilising and destabilising changes. A stringent cut-off was applied 
when assigning stabilising or destabilising variants: above 140% of wild-type stability were assigned as stabilis-
ing and below 80% of wild-type stability as destabilising. Those in the destabilised category may also represent 
protein with reduced expression levels. Importantly, these datasets only inform on the most likely positions for 
stabilisation when changed to alanine (or leucine if the native residue was alanine) as this was the information 
provided by the GPCR datasets.
Each of the input GPCRs were run through the following bioinformatics tools: PsiPred for secondary structure 
 prediction14, DisoPred for disorder prediction, MemSatSVM for membrane  topology60, RYTHEM for lipid and 
helix contact  prediction61, and  JackHMMER59 for multiple sequence alignment and conservation extraction.
The data were weighted to allow comparison between the different bioinformatic factors. This was done 
by applying abundance weighted scoring: the frequency with which a factor was associated with stabilising or 
destabilising effects and internally normalised to the total number of observations for that factor. This reduced 
the skew towards common factors, allowing better comparisons between the stabilising properties of, for exam-
ple, highly abundant (e.g. alanine) and rare residues (e.g. tryptophan) (Fig. S1). We were able to derive a simple 
scoring matrix in which factors least associated with destabilising changes and most associated with stabilising 
changes scored the highest. For example, glutamine was the 4th amino acid most associated with stabilising 
changes (score of 17/20), and was the amino acid least associated with destabilising changes (score of 20/20), 
providing an overall score of 37 (Table S1).
This scoring method forms the basis used by the data-driven module of IMPROvER to rank positions. A 
final score was given to each position in the protein, calculated as the product of multiplying scores of five bio-
informatic factors together (Table S1): (1) amino acid identity, (2) topology, (3) conservation, (4) lipid contact 
prediction and 5) helix contact prediction. Each individual factor was trialled for predictive power before using 
them in combination, and using them in combination was the most powerful predictive method (Fig. 2A,B). 
Disorder prediction was not included at the time of testing in vitro targets, but has been included in the final 
version IMPROvER as overall prediction is slightly increased when included against the GPCR test set. The 
baseline for random selections of variants was established as 7.6 (± 1.0; SD n = 10) stabilisers or 48.5 (± 5.9; SD 
n = 10) destabilisers per 100 amino acids by ten random samplings of the input data.
Primer design. The primers designed for this study, and the ones that IMPROvER automatically creates, are 
non-overlapping primers for inverse PCR site-directed  mutagenesis62. They create a PCR product of the whole 
plasmid, where the ends are joined by blunt-end ligation. The primer melting temperature calculation used 
for selecting primer length is based on the “nearest-neighbour”  method63, which takes experimentally derived 
values for the energy required to melt a given 2 bp stretch, and estimates a whole primer in terms of Gibbs free 
energy required Eq. (1).
where Cp is the primer concentration, H◦ is enthalpy (cal mol−1 ), S◦ is entropy (cal K−1 mol−1 ) and R is the 
universal gas constant (1.987 cal K−1 mol−1)
Forward primers were designed to have at least 10 bps either side of the mismatch, but more on the 3′ side 
depending on primer melting temperature. The primer is iteratively minimised to an ideal melting temperature 
between 65 and 70 ◦ C by adding or removing bases from the 3′ end. The reverse primer is iteratively minimised 
(1)primer melting temperature =
(�H◦i +H
◦)× 1000
�S◦i +�S
◦ + R × lnCp
− 273.15
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to match the melting temperature of the forward primer. Primers are then subjected to further optimisation, 
refining the melting temperature as close to 62 ◦ C as possible so that a single annealing temperature can be used 
for all mutations during PCR amplification.
Gene constructs and mutagenesis. Unless stated otherwise, enzymes and buffers for molecular clon-
ing were obtained from New England Bioscience (NEB). For studies of ClPPase, the protein coding region for 
the putative K+-stimulated pyrophosphate-energised dual Na+/H+ pump from Clostridium leptum (UniProt: 
A7VNH8) was made synthetically with the addition of an N-terminal 8xHis-tag and superfolder GFP followed 
by a TEV protease cleavage site (ENLYFQ). This construct was transferred to a pDDGFP yeast expression 
 plasmid64 by homologous recombination, displacing an existing yGFP tag in the backbone and putting the gene 
under the control of the galactose promoter. For studies of hENT1, a pFastBac plasmid containing the hENT1 
protein coding sequence from the gene slc29a1 (UniProt: Q99808), which had been C-terminally tagged with 
eGFP-His6 and separated by a TEV protease cleavage site (ENLYFQ) was obtained from previous  studies65. For 
studies of PTH1R , the truncated human receptor (residues 180–593) was cloned into a pFastBac plasmid with 
a C-terminal GFP-His8 tag. To improve expression, the extracellular domain was replaced with apocytochrome 
b562RIL (BRIL) using an In-Fusion HD Cloning Plus kit following the manufacturer’s protocol (Takara-Bio).
For inverse PCR to amplify whole plasmids, 5µL of 2 × Q5 polymerase pre-mix was mixed with 1 ng µL−1 
template DNA, 0.5µM of forward and 0.5µM of reverse primer, and made to a final volume of 10µL in nuclease 
free H2O . The reaction was performed using a T100 thermocycler (Bio-Rad) with the following program: initial 
heat activation at 98 ◦ C for 5 min, cycling through 30 s of denaturation at 98 ◦ C, 30 s of annealing at 65 ◦ C 
and 3 min of extension at 72 ◦ C 30 times, followed by a final extension for 5 min at 72 ◦ C and holding at 8 ◦ C. 
PCR products were then subjected to blunt-end ligation in the presence of DpnI restriction enzyme by mixing 
a 2:1:1:1 ratio of DpnI, T4 DNA ligase, T4 polynucleotide kinase and 10 × T4 DNA ligase buffer, respectively, 
adding 2µL of this mixture to 10µL of PCR product and incubating for 1 h at 20 ◦ C. 2µL of this reaction was 
then transformed into chemically competent OmniMax cells by heat-shock (20 min at 4 ◦ C, 45 s at 42 ◦ C and 
2 min at 4 ◦ C) in 96-well PCR plate format for high-throughput. Following heat-shock, cells were recovered at 
37 ◦ C for 1 h in LB medium before being spread on LB agar plates containing 50µg mL−1 carbenicillin. After 16 h 
at 37 ◦ C, colonies were picked for overnight culture in 4 mL LB medium with 50µg mL−1 ampicillin. Plasmids 
were then mini-prep isolated (Machery Nagel) and DNA sequencing (Eurofins) over the region of mutagenesis 
to confirm correctly incorporated variants. Some mutations required multiple rounds of reactions before suc-
cessful site mutation was confirmed.
Yeast culture and expression of ClPPase. The S. cerevisiae strain FGY217 (genotype: MATα , ura3-52, 
pep 4, lys2201)66 was incubated at 30 ◦ C for 72 h on YPD plates (2% (w/v) peptone, 1% (w/v) yeast extract, 
2% (w/v) d-glucose, 2.5% (w/v) agar). Per transformation, 1 mL YPD media was inoculated with a colony grown 
on the YPD plate and incubated at 30 ◦ C overnight. Cells were then harvested by centrifugation at 3,000×g for 
5 min and washed in 1 mL sterile ultra pure H2O three times. During the final washing step, the cell suspension 
was split into 1 mL aliquots prior to discarding the supernatant. The cell pellet was resuspended in 360µL sterile 
transformation mixture containing 10 mM lithium acetate, 33.3% (w/v) PEG 3350, 100µg denatured fish sperm 
DNA and 100–500 ng plasmid. Heat-shock was carried out at 42 ◦ C for 40 min to trigger DNA uptake by the 
cells. Cells were centrifuged at 3,000×g for 5 min and the pellet was resuspended in 200µL of sterile H2O . The 
resuspension was spread onto an SCD-Ura plate (0.67% (w/v) yeast nitrogen base, 2% (w/v) d-glucose, 2% (w/v) 
agar, 0.1 mg mL−1 carbenicillin, 105 mg mL−1 l-threonine, 26 mg mL−1 l-phenylalanine, 16 mg mL−1 l-lysine, 
10.5 mg mL−1 of l-arginine, 10.5 mg mL−1 l-histidine, 10.5 mg mL−1 l-leucine, 10.5mg mL−1 l-methionine, 
10.5 mg mL−1 l-tryptophan, 10.5 mg mL−1 l-tyrosine, 10.5 mg mL−1 l-adenine) and incubated for 3  days at 
30 ◦ C. A single colony was transferred to 5 mL of SCD-Ura media and incubated at 30 ◦ C for 16 h. This starter 
culture was used to inoculate 15  mL SCD-Ura media for single-temperature GFP-based stability assays or 
100 mL SCD-Ura media for ten-temperature stability assay at an OD600 of 0.15. The expression cultures con-
tained 0.1% d-glucose instead of 2% d-glucose and were incubated at 30 ◦ C for 5–6 h. ClPPase expression was 
induced at an OD600 of 0.6 by addition of 2% d-galactose and allowed to continue for 15 h at 30 ◦ C. Cells were 
harvested by centrifugation at 3,000×g for 5 min.
Stability testing of ClPPase. Cell pellets were resuspended in 750µL lysis buffer (200 mM tris-HCl pH 
7.5, 40% (w/v) glycerol, 10 mM EDTA, 2 mM dithiolthreitol (DTT), 2µg mL−1 pepstatin A, 0.2 mM PMSF) 
and transferred into 2 mL tubes containing approximately 1.3 g of glass beads (0.5 mm diameter). The tubes 
were placed in a 24-tube adapter (Qiagen Catalogue number: 13000-V1-24) for a Vortex-Genie 2 (Scientific 
Industries) and vortexed at maximum speed for 30 min at 4 ◦ C to lyse the cells. Cell debris and glass beads were 
subsequently removed by centrifugation at 8,000×g, 4 ◦ C for one min. The membranes were harvested by cen-
trifugation at 36,000×g, 4 ◦ C for 1 h and the pellet was solubilised in a total volume of 150µL for a single point 
GFP-fluorescence-based stability assay, or 750µL for a full ten-temperature GFP-fluorescence-based melting 
curve in 50 mM MES pH 6.5, 20% (w/v) glycerol, 37.5 mM KCl, 3.75 mM MgCl2 , 1 mM Na4P2O7 , 1.34% (w/v) 
dodecylmaltoside (DDM), 1 mM DTT, 0.15µg mL−1 pepstatin A, and 0.25 mM PMSF. Solubilisation took place 
at 4 ◦ C for 1.5 h in 1.5 mL tubes continuously mixed by rolling. Residual insoluble material was removed by 
centrifugation at 37,000×g, 4 ◦ C for 1 h. The fluorescence signal of the supernatant was measured using a QFX 
Fluorometer (DeNovix) to confirm the presence of GFP-tagged protein. All samples were diluted to the lowest 
fluorescence reading obtained within a set of samples to allow direct comparison between them. For screening 
experiments using the single-temperature GFP-based stability assay, the samples were split into two 60µL ali-
quots. One remained on ice and one was heated to 50 ◦ C for 10 min in a Thermomixer (Eppendorf). For melt-
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ing curve recordings of wild-type and ClPPase variants, detergent-solubilised sample was split into 11 aliquots 
of 60µL . One aliquot remained on ice while the others were independently incubated at a range of different 
temperatures (20, 30, 40, 45, 50, 55, 60, 70, 80 or 90 ◦C). Afterwards, the samples were placed on ice for 30 min 
prior to centrifugation at 20,000×g, 4 ◦ C for 30 min. 40µL of the supernatant was subsequently transferred into 
fresh tubes and mixed with 10µL of 5 × SDS-PAGE loading buffer (10% (w/v) SDS, 100 mM DTT, 50% (w/v) 
glycerol, 500 mM tris and 0.05% (w/v) bromophenol blue). 15µL of each sample was loaded onto 4–20% Mini-
PROTEAN TGX gels (Bio-Rad) and run at 150 V for 1 h. ClPPase bands were visualised by in-gel fluorescence 
detection using the G:BOX (G:BOX Chemi XX6 with Blue LEDs; Syngene). Data is representative of up to three 
biological repeats for variant, and up to eight biological repeats for wild-type ClPPase (Table S2).
Phosphate release assay of ClPPase. The hydrolytic activity of wild-type and variant ClPPase in the 
membrane was assessed using a colorimetric phosphate release assay as previously  described67, 68. In brief, the 
resuspended membranes were diluted with buffer containing 50 mM MES pH 6.5, 20% (w/v) glycerol, 50 mM 
KCl, 5 mM MgCl2 , 1.33 mM DTT, 0.2µg mL−1 pepstatin A and 0.335 mM PMSF to a total membrane protein 
concentration between 2 and 4mg mL−1 . Assay solution A (17 mM ascorbic acid in ice-cold 0.5 M HCl) and B 
(6 mM ammonium-heptamolybdate in ice-cold ultra pure H2O ) were prepared fresh and stored on ice until use. 
Either 5µL of diluted membranes or Pi standard at 0.2, 0.5, 2, 4, 6, 8 or 10 mM was mixed with 35µL reaction 
mixture (171 mM tris-HCl pH 8, 7 mM MgCl2 , 286 mM KCl, 57 mM NaCl, 2.85 mM NaF, 0.01 mM Gramicidin) 
and transferred to PCR-tubes. Samples and standards were prepared in triplicate. They were pre-incubated to 
30 ◦ C for 5 min before the addition of 10µL 2 mM tetrabasic sodium pyrophosphate. The reaction was allowed 
to proceed for 10 min at 30 ◦ C before samples were cooled on ice to quench. As a negative control, 5µL of diluted 
membrane was added to the reaction mixture treated the same as samples and standards, but membranes were 
added after the reaction had been quenched. After 10 min on ice, 60µL of a 1:1 mixture of assay solution A and 
B was applied to each tube and the samples were kept on ice for a further 10 min. 90µL of sodium arsenite solu-
tion in 2% acetic acid (68 mM tribasic sodium citrate, 154 mM sodium arsenite) was added and the tubes were 
incubated at room temperature for 1 hour. The absorbance at 860 nm was measured using a Spark microplate 
reader (Tecan). Specific protein concentration of wild-type or variant ClPPase expressed in the membranes was 
estimated by measuring eGFP fluorescent signal against an eGFP calibration curve recorded using a QFX Fluo-
rometer (DeNovix). Specific activity was calculated as the amount of phosphate released per min for a known 
amount of wild-type or variant ClPPase in the membrane (µmol Pi min−1 mg−1).
Insect cell culture and expression of hENT1 and hPTH
1
R. In general, hENT1 and hPTH1R variants 
in pFastBac plasmid were transferred to Bacmids following manufacturer’s recommendations (Bac-to-Bac bacu-
lovirus expression system; Invitrogen). Briefly, DH10Bac E. coli (Invitrogen) were heat shock transformed with 
pFastBac-hENT1 or hPTH1R variant plasmids using a 96-well PCR plate format for high-throughput. Following 
recovery in LB medium for 16 h, cells were spread on LB agar plates with 50µg mL−1 kanamycin, 7µg mL−1 
gentamicin, 10µg mL−1 tetracycline, 100 mM IPTG and 0.2% Bluo Gal (Invitrogen). Following 72 h incubation 
at 37 ◦ C, suspected white colonies were re-streaked onto fresh LB agar plates with the same antibiotics and left 
for a further 24 h to confirm disruption of the β-galactosidase gene (lacz) by successful homologous recombi-
nation into the bacmid DNA. Confirmed white colonies were selected for overnight culture in 2 mL LB with 
50µg mL−1 kanamycin, 7µg mL−1 gentamicin and 10µg mL−1 tetracycline. Bacmid DNA was then isolated 
from pelleted cells (10 min, 3,000× g, 20 ◦ C) by re-suspension in 50 mM tris-HCl pH 8.0, 10 mM EDTA and 
100µg mL−1 RNaseA, cell lysis in 200 mM NaOH and 1% SDS, neutralisation in 4.2 M guanidinium-HCl and 
0.9 M potassium acetate pH 4.8, clarification (10 min, 16,000× g, 20 ◦C), precipitation and washing in ice cold 
40% isopropanol, pelleting (10 min, 16,000×g, 4 ◦C), final washing in ice cold 70% ethanol, and re-suspension 
in ultra pure H2O.
Following isolation, bacmids were transfected into Sf9 insect cells using an adherent cell culture protocol 
scaled for 24-well plate format for high-throughput as follows: fresh mid-log phase Sf9 cells were diluted to a den-
sity of approximately 0.55× 106 cells mL−1 in Insect-XPRESS Protein-free media (Lonza). These cells were dis-
tributed in 2 mL aliquots into each well of a poly d-lysine coated 24-well flat-bottom cell culture plate (Sarstedt), 
and left to adhere to the surface for 30 min. XtremeGENE HP Transfection Reagent (Roche) was diluted 1:10 in 
Insect-XPRESS Protein-free media (Lonza) to 100µL and bacmid DNA added to 10 ngµL−1 . This transfection 
mixture was incubated at room temperature for 30 min before being added to the adherent cells. The plate was 
sealed and incubated for 3 days at 27 ◦ C. Medium containing virus was removed from the top of the adherent 
cells to form the initial stock of virus. 2 mL fresh, pre-warmed Insect-XPRESS Protein-free media (Lonza) was 
added to the cells and the plate incubated for a further 3 days. The cells were then imaged using an EVOS FL 
fluorescence confocal microscope for confirmation of GFP expression and plasma membrane localisation.
Virus amplification cultures were set up to both increase the volume of virus available for further infections 
and to increase the viral titre. Fresh mid-log phase Sf9 cells were diluted to 1.0 × 106 cells mL−1 in Insect-XPRESS 
Protein-free media (Lonza) and distributed in 2.5 mL aliquots into each well of a sterile 24-well deep-well block 
with round bottoms. To each well, 25µL of the initial virus from adherent cultures was added to begin infection 
and viral amplification. Cultures were incubated at 27 ◦ C for 3 days on an orbital shaker at 450 rpm. Amplified 
virus was then harvested by aspirating the media from the cell pellets following centrifugation of the cultures at 
1,000×g, 4 ◦ C for 10 min in swing-out plate adaptors.
Expression cultures were set-up using fresh mid-log phase Sf9 cells, diluted to a density of approximately 
2.0 × 106 cells mL−1 in 2.5 mL or 25 mL of 27 ◦ C pre-warmed Insect-XPRESS medium (Lonza) for hENT1 
or hPTH1R , respectively. For hENT1, cultures were set-up in wells of a sterile 24-well deep-well block with 
round bottoms, whereas hPTH1R cultures were set up in 125 mL sterile culture vessels. For hENT1, 50µL of 
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the amplified virus was added to each well to begin infection and expression of the hENT1 variants in a high-
throughput mode. For hPTH1R , 10µL of V1 virus was added to each culture to begin infection and expression of 
the hPTH1R variants. Cultures were incubated at 27 ◦ C for 3 days with shaking on an orbital shaker at 450 rpm. 
Cells were then harvested by centrifugation at 1,000×g, 4 ◦ C for 10 min, frozen and stored at − 80 ◦ C until use. 
Expression cultures were performed in four biological repeats for hENT1 or three biological repeats for hPTH1R.
Stability testing of hENT1 and hPTH
1
R. Each insect cell pellet was resuspended in 300µL of resuspen-
sion buffer (50 mM tris-HCl, pH 7.5, 1 × Protease Inhibitor Cocktail) for hENT1, or 1 mL of 1 × phosphate-
buffered saline (PBS) with protease inhibitor cocktail. Cell resuspensions were solubilised by the addition of 1% 
(w/v) DDM, carried out with inversions for 1 h at 4 ◦ C. Solubilised protein was then isolated by centrifugation 
(21,000×g, 4 ◦ C for 1 h). For screening experiments using the single-temperature GFP-based stability assay, the 
supernatants were split into two aliquots of 50µL between two 96-well PCR plates (one well per hENT1 variant). 
One PCR plate remained on ice and one was heated to 50 ◦ C or 39 ◦ C (for hENT1 or hPTH1R , respectively) 
for 10 min in a T100 thermocycler (Bio-Rad). Each independent PCR plate had at least one wild-type repeat 
for comparison across different rounds of testing. For ten-temperature melting analysis of wild-type, pellets 
from larger cultures (scaled up tenfold) were obtained and protein solubilised equivalently to single temperature 
assays. One 50µL aliquot remained on ice while the others were successively incubated at a range of different 
temperatures (30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or 85 ◦ C for hENT1, or 4, 34, 36, 38, 40, 42, 45, 54, and 60 ◦ C 
for hPTH1R ). Following heating, samples were cooled to 4 ◦ C and kept on ice until centrifugation at 21,000×g, 
4 ◦ C for 35 min. 40µL of each supernatant was then transferred to a fresh well of a PCR plate and 10µL of 5 × 
SDS-PAGE loading buffer added to each. 15µL of each sample was loaded onto 4–20% Mini-PROTEAN TGX 
gels (Bio-Rad) and run at 150 V for 1 h. In-gel hENT1 or hPTH1R linked GFP-fluorescence was visualised using 
a G:BOX (G:BOX Chemi XX6 with Blue LEDs; Syngene). Data is representative of three biological repeats for 
single-temperature and ten-temperature assays, of which two sets of the ten-temperature assays were used for an 
additional technical repeat (n = 5 total) (Table S4).
Inhibitor binding assay of hENT1. The remaining insect cell pellet of hENT1 variants was used for inhib-
itor binding assays. Each cell pellet was resuspended in 500µL of resuspension buffer (50 mM tris-HCl, pH 7.5, 
1 × cOmpleteTM protease inhibitor cocktail). The optical density of each cell resuspension was measured at 
600 nm to inform normalisation. A working stock of [Benzyl-3H]-nitrobenzylthioinosine (PerkinElmer) ([3H]-
NBMPR) was prepared by diluting stock [3H]-NBMPR in resuspension buffer to a final concentration of 2µCi 
mL−1 (64 nM). The cell resuspensions were divided into ten 50µL aliquots for three technical repeats of three 
assay conditions.
The nine assay aliquots were incubated in three conditions: (1) no inhibitor (−/−), (2) 32 nM [3H]-NBMPR ( +
/−), (3) 32 nM [3H]-NBMPR and 20µM dipyridamole ( +/+ ). All conditions were incubated at room temperature 
for 1 h. Samples were applied to a GF/B filter (Whatman) pre-equilibrated in washing buffer (50 mM tris-HCl, 
pH 7.5) on a vacuum manifold (Promega). The liquid was pulled through the filters under vacuum, and washed 
three times with 2 mL of buffer (50 mM tris-HCl, pH 7.5). Filters were incubated overnight at room temperature 
in 10 mL of Ultima Gold scintillant (PerkinElmer). Radioactive disintegrations from bound [3H]-NBMPR in 
samples were quantified in counts per min using a TriCarb scintillation counter (PerkinElmer) using 10-min 
reads, which were performed twice. Deduction of background (−/−) and non-specific binding ( +/+ ) allowed 
for the determination of hENT1 variant specific binding, and specific radioactive signal was normalised for 
each sample using total in-gel GFP-signal for each hENT1 variant, and then scaled relative to wild-type binding.
Statistical analysis. GFP signal intensity of hENT1, hPTH1R and ClPPase bands after single and ten-tem-
perature stability assays was quantified using  ImageJ69 (Figs. S2, S7). The Tm of wild-type and variant protein was 
obtained by plotting the fluorescence signal, normalised to the on-ice sample, against temperature challenges 
and data fitting with a four-parameter dose-response curve (variable slope) by non-linear least-squares fitting 
in the python package scipy.stats. The inflection point of the fitted melting curve represents the Tm at which half 
of the protein is denatured. The standard error of the mean (SEM) of Tm and Tm determination was calculated 
where n > 1 (Tables S2, S4, S6). Error propagation was factored in using Eq. (2).
Data availability
Data generated in this study will be made available upon request to the authors. The IMPROvER pipeline is avail-
able for academic users by visiting http://impro ver.ddns.net/IMPRO vER/. For commercial use of IMPROvER, 
users will be asked to obtain a licence from the University of Leeds.
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